NCT06296836 Effect of Continuing Versus Holding Metformin During Hospitalizations.
| NCT ID | NCT06296836 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of Illinois at Chicago |
| Condition | Diabetes Mellitus, Type 2 |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-01-21 |
| Primary Completion | 2026-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 300 participants in total. It began in 2025-01-21 with a primary completion date of 2026-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A randomized study of continuing versus holding metformin during hospitalizations to internal medicine services to determine the effects on glucose control, acidosis, abdominal symptoms, length of stay, and mortality.
Eligibility Criteria
Inclusion Criteria: * Adult (18+ years of age) * Admitted to an internal medicine service. * On Metformin prior to admission. Exclusion Criteria: * Inability to take oral medications * eGFR \< 30 ml/min/1.73 m2 * Dialysis * Current Acidosis (pH \< 7.35) including diabetic ketoacidosis * Child-Turcotte-Pugh class C hepatic cirrhosis * Acute Decompensated Heart Failure * Cognitively impaired and/or unable to consent * Lack of or unwillingness to share contact information * Pregnant women
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06296836 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 110 Years, studying Diabetes Mellitus, Type 2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06296836 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06296836 currently recruiting?
Yes, NCT06296836 is actively recruiting participants. Contact the research team at mthambi@uic.edu for enrollment information.
Where is the NCT06296836 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT06296836 clinical trial?
NCT06296836 is sponsored by University of Illinois at Chicago. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.